MAXZIDE AND DYAZIDE COMPARATIVE DOSAGES

Reproduced by "The Pink Sheet" from initial labeling for Maxzide and most recent PDR labeling version for Dyazide. MAXZIDE DOSAGE AND ADMINISTRATION -- The recommended dosage of MAZXIDE is one tablet daily with appropriate monitoring of serum potassium levels (see WARNINGS). Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE directly. In patients requiring 50 mg of hydrochlorothiazide in whom hypokalemia cannot be risked, therapy may be initiated with MAXZIDE. There is no clinical experience with doses exceeding one tablet daily. Clinical studies have shown that patients already taking less bioavailable formulations of triamterene and hydrochlorothiazide (totaling 50-100 mg of hydrochlorothiazide and 100-200 mg of triamterene) may be safely changed to one MAXZIDE tablet per day.; these patients should be monitored clinically and with serum potassium after the transfer. DYAZIDE DOSAGE AND ADMINISTRATION -- As determined by individual titration. Adults: The usual dose is one or two capsules twice daily after meals. Some patients may be maintained on one capsule daily or every other day. Maximum daily dose should not exceed four capsules, and at this dosage, the incidence of side effects may increase. Since 'Dyazide' has an antihypertensive effect, hypotensive drugs used concomitantly should be added at reduced dosage -- at least one half the usual dosage -- particularly if it is a ganglionic or peripheral adrenergic blocking agent. Adjust dosage as indicated. Children: Adequate information on the use of 'Dyazide' in children is not available. Note: Potassium supplementation used concurrently with other diuretics should be discontinued when titrating with Dyrenium (triamterene, SK&F Co.). They should not be reinstituted when the patient is placed on 'Dyazide' unless the triamterene component does not completely compensate for the potassium loss.

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.